Skip to main content
. 2021 Sep 15;11(9):4470–4484.

Figure 3.

Figure 3

Asciminib and ponatinib synergize in inhibiting CRKL phosphorylation in human CML cell lines. KU812, K562, KCL22 and KCL22T315I were kept in control medium (Control) or in the presence of asciminib (Asci), ponatinib (Pona) or a combination (Combi) of both drugs as indicated for 4 hours before expression of p-CRKL and β-tubulin (loading control) were analyzed by Western blotting.